ClinicalTrials.gg
CompletedNCT04877379Updated Dec 8, 2025

VNRX-7145 Drug-Drug Interaction in Healthy Adult Volunteers

A Phase 1 interventional study of VNRX-7145 and VNRX-5024 (ceftibuten) in Healthy Subjects, sponsored by Basilea Pharmaceutica. Completed at 1 site in Netherlands. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-08.

Sponsored by Basilea Pharmaceutica · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
53
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This study will provide an initial assessment of the safety and PK of VNRX-7145 and VNRX-5024 (ceftibuten) when administered as single agents and with co-administration in a single dose cross-over design in Part 1. In Part 2, subjects will receive 500 mg of VNRX-7145 or matching placebo q8h for 10 days. VNRX-7145 and VNRX-5024 (ceftibuten) will be administered every 8 hours (q8h) for 10 days at 2 dose levels of VNRX-7145 in Part 3.

02

Conditions studied

  • Healthy Subjects
03

In context

Lead sponsor

Basilea Pharmaceutica is the lead sponsor of 60 studies on the registry; 7 are open to participants now.

Of its 22 completed or terminated interventional studies of FDA-regulated products, 15 (68%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy adults 18-55 years
  2. Males or non-pregnant, non-lactating females
  3. (BMI): ≥18.5 kg/m2 and ≤32.0 kg/m2
  4. Normal blood pressure
  5. Normal lab tests

Exclusion criteria

Exclusion Criteria:

  1. History or presence of current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, , hematologic, neoplastic, or neurological disorders
  2. History of drug allergy or to penicillin, cephalosporin, or beta-lactam antibacterial drug
  3. Use of antacid medications
  4. Abnormal or history of abnormal rhythm disorder
  5. Positive alcohol, drug, or tobacco use/test
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
53 participants (actual)

Study arms

  • Experimental
    Part 1

    Subjects will receive single doses of VNRX-7145 or VNRX-5024 alone and in combination. All subjects will receive study drug in the sequence specified by the randomization schedule.

    Drug: VNRX-7145 · Drug: VNRX-5024 (ceftibuten)

  • Experimental
    Part 2A

    Multiple dose administration of VNRX-7145 q8h for 10 days

    Drug: VNRX-7145

  • Placebo comparator
    Part 2B

    Multiple dose administration of placebo q8h for 10 days

    Drug: Placebo

  • Experimental
    Part 3A

    Multiple dose administration of low dose VNRX-7145 + VNRX-5024

    Drug: VNRX-7145 · Drug: VNRX-5024 (ceftibuten)

  • Experimental
    Part 3B

    Multiple dose administration of high dose VNRX-7145 + VNRX-5024

    Drug: VNRX-7145 · Drug: VNRX-5024 (ceftibuten)

  • Placebo comparator
    Part 3C

    Multiple dose administration of Placebo (matching VNRX-7145 + VNRX-5024)

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Part 1: Cmax

    concentration time data

    Time frame: 0-48 hours

  2. Part 1: AUC0-inf

    Area under the concentration-time curve from time-zero extrapolated to infinity based on collected PK

    Time frame: 0-48 hours

  3. Parts 2&3: Number of subjects with adverse events

    Time frame: Day 15 (+2)

Secondary outcomes

  1. Part 1: Number of subjects with adverse events

    Time frame: Day 14 (+2)

  2. Parts 2&3: AUC0-tau

    Time frame: Day 1

  3. Parts 2&3: AUC0-tau

    Time frame: Day 10

  4. Parts 2&3: Cmax

    Time frame: Day 1

  5. Parts 2&3: Cmax

    Time frame: Day 10

07

Study locations

1 site
  • PRA Health Sciences - Early Development Services
    Groningen, Netherlands
08

References and documents

Publications

  • de Oliveira CF, Dorr MB, van de Wetering J, Lowe K, Sabato P, Winchell G, Chen H, McGovern PC. Safety and pharmacokinetics of single and multiple doses of ledaborbactam etzadroxil with or without ceftibuten in healthy volunteers. Antimicrob Agents Chemother. 2025 Sep 3;69(9):e0021025. doi: 10.1128/aac.00210-25. Epub 2025 Aug 5. PubMed 40762486 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2021 to primary completion in Nov 2021, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 3, 2021
First posted
May 7, 2021
StartActual
Jun 8, 2021
Primary completionActual
Nov 10, 2021
CompletionActual
Nov 10, 2021
Last update
Dec 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04877379
Responsible party
Sponsor
First posted
May 7, 2021
Start date
Jun 8, 2021
Primary completion
Nov 10, 2021
Completion
Nov 10, 2021
Last update
Dec 8, 2025

Study contacts

Kamal Hamed, MD
study director · Basilea Pharmaceutica International Ltd, Allschwil

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ledaborbactam etzadroxil · Ceftibuten

Start the discussion